Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I M Werter

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Netherlands Journal of Medicine|January 8, 2014
Head and neck paragangliomasI M Werter, C Rustemeijer
International Journal of Radiation Oncology, Biology, Physics|January 10, 2026
Toxicity and Treatment Completion of Neoadjuvant FOLFOXIRI and Chemoradiotherapy in patients with High-Risk Locally Advanced Rectal Cancer: A Secondary Outcome Analysis of the MEND-IT TrialE Banken, K van den Berg, I E G van Hellemond, et al.
BMC Cancer|September 6, 2022
Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)K van den Berg, D P Schaap, E L K Voogt, et al.
BMC Cancer|May 19, 2026
A national, multicentre, randomised, controlled, parallel-arms, phase III clinical trial of neoadjuvant FOLFOXIRI and chemoradiotherapy versus neoadjuvant CAPOX/FOLFOX and chemoradiotherapy in patients with high-risk locally advanced rectal cancer: study protocol of the MEND-IT II trialE Banken, M Borg, I E G van Hellemond, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Netherlands Journal of Medicine|January 8, 2014
Head and neck paragangliomasI M Werter, C Rustemeijer
International Journal of Radiation Oncology, Biology, Physics|January 10, 2026
Toxicity and Treatment Completion of Neoadjuvant FOLFOXIRI and Chemoradiotherapy in patients with High-Risk Locally Advanced Rectal Cancer: A Secondary Outcome Analysis of the MEND-IT TrialE Banken, K van den Berg, I E G van Hellemond, et al.
BMC Cancer|September 6, 2022
Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)K van den Berg, D P Schaap, E L K Voogt, et al.
BMC Cancer|May 19, 2026
A national, multicentre, randomised, controlled, parallel-arms, phase III clinical trial of neoadjuvant FOLFOXIRI and chemoradiotherapy versus neoadjuvant CAPOX/FOLFOX and chemoradiotherapy in patients with high-risk locally advanced rectal cancer: study protocol of the MEND-IT II trialE Banken, M Borg, I E G van Hellemond, et al.
Pageof 1